About this trial
Mold invasive infections are associated with an important mortality despite optimization of the antifungal treatment. In a few case reports, immune checkpoints inhibitors, initially developed for neoplastic diseases, have shown a potential beneficial effect in such devastating infections by restoring an efficient immune response. The investigators propose a longitudinal monitoring of the adaptative immune response, notably immune checkpoint expression on T cells, during mold invasive infections to help identify the patients who could benefit from the adjunction of immunotherapy and the optimal timing of such strategy.
Eligibility criteria
Qualifiers
Age ≥ 18 years
Mold invasive fungal infection: Aspergillus, Mucorales, Fusarium, Scedosporium
Proven or probable according to 2019 EORTC/MGS criteria modified by the adjunction of diabetes mellitus in the host criteria and Mucorales PCR in the microbiological criteria
Within 14 days of IFD diagnosis or
Disqualifiers
Bacterial co-infection in the last 14 days
Previous treatment with anti-PD1 antibodies
Trial design
Treatments tested in this trial
- Not listed
Trial groups
Sponsors and collaborators
Assistance Publique - Hôpitaux de Paris
Lead sponsor
URC-CIC Paris Descartes Necker Cochin
Collaborator